Biotech Values

[rkrw]

Randy, not to be a wet blanket, I'm sure there are many more cases, but one real life example is itmn/actimmune for ipf. An australian investigator showed stunning phase II results that weren't replicated in itmn's pivotal trial. Your comments are just about the same as mine were about itmn prior to the actual outcome. Turned out in the phase II there likely was biased patient selection going on and further it couldn't be confirmed that all the australian patients indeed had ipf, in fact a few didn't.

I do hope like heck the phase II data are very good and confirm what was seen in Mexico.